Market news

ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Board of Directors. Attachment notification-of-managers-transaction-lionel-carnot-14-september-2026

The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' transaction - Anthony Rosenberg - 13 August 2026 RSU vest Notification of managers' transaction - Christina Ackermann - 13 August 2026 RSU vest Notification of managers' transaction - Arshad Khanani - 13 August 2026 RSU vest Notification of managers' transaction - Robert Warner - 13 August

The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in Oculis Holding AG (OCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050,000 Oculis ordinary shares subject to lockup release over a period of up to 2 years, or vesting upon achievement of development and regulatory milestonesPrivosegtor, a neuroprotective drug candidate, is currently being investigated in registrational trials with initial indications

Detailed price information for Oculis Holding Ag (OCS-Q) from The Globe and Mail including charting and trades.

Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS) relapses following positive FDA pre-IND feedbackEnrollment progressing as planned in the PREDICT-1 genotype-based registrational trial of Licaminlimab in dry eye disease with all planned sites activated and >45% patients randomized Cash, cash equivalents, and short-term investments of $282.3 millio

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical needThe FDA confirmed that existing Privosegtor data can be cross-referenced for a new Investigational New Drug (IND) application in acute MS relapses, planned for submission in the fourth quarter of 2026Privosegtor, a novel neuroprotective candidate, continues